| 000 | 01671 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250514162500.0 | ||
| 264 | 0 | _c20040817 | |
| 008 | 200408s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1704277 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBenesch, M | |
| 245 | 0 | 0 |
_aLack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cDec 2003 |
||
| 300 |
_a1071-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmifostine _xadministration & dosage |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 |
_aCytoprotection _xdrug effects |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xadministration & dosage |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xcomplications |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aSiblings |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xadverse effects |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aWhole-Body Irradiation |
| 700 | 1 | _aMcDonald, G B | |
| 700 | 1 | _aSchubert, M | |
| 700 | 1 | _aAppelbaum, F R | |
| 700 | 1 | _aDeeg, H J | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 32 _gno. 11 _gp. 1071-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1704277 _zAvailable from publisher's website |
| 999 |
_c14362243 _d14362243 |
||